Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, together with the Medical University Vienna today presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
SYDNEY, Australia – 3 April 2019 –Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, together with the Medical University Vienna today presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
Highlights of the presentation included:
- Research led by Prof Wierdermann successfully inhibited tumor growth in a syngeneic mouse model of HER-2+ breast cancer via both passive and active immunisation strategies with PD-1 targeting B-cell cancer vaccines.
- For the active immunisation study, which is of greatest interest and potential value to cancer researchers, the surrogate vaccine derived from mouse PD-1 was able to “brake tolerance” thereby inducing a sustained antibody response to the self-protein PD-1.
- The findings provide proof of concept and validation for the human PD-1 cancer vaccine KEY-Vaxx.
The presentation by Dr Joshua Tobias from the Medical University Vienna, was entitled ‘PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity and anti-tumor activity: New strategy for a multi-level cancer immunotherapy.’
The presentation was authored by Dr Tobias and Professor Ursula Wiedermann from the Medical University Vienna together with leading researchers from the University of Gothenburg Sweden, the University of Veterinary Medicine Vienna and the Vienna Cancer Centre Austria
The Medical University Vienna and Imugene are working to develop mimotope based cancer vaccines.
The content of the poster presentation is available on the Imugene website: www.imugene.com/
- ENDS -
Notes To Editors
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Find out more at www.imugene.com.
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
Issued for and on behalf of Imugene by Instinctif Partners.
For more information please contact:
Imugene
Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com
City Public Relations (Australia Media enquiries):
Andrew Geddes
T: +61 (02) 9267 4511
E: ageddes@citypublicrelations.
Instinctif Partners (International Media enquiries):
Sue Charles / Genevieve Wilson
T: +44 (0)20 7457 2859
E: imugene@instinctif.com
